Several other MCL-1 inhibitors [AZD5991(AstraZeneca), AMG-176, AMG-397(Amgen), S64315/MIK665(Novartis)] are currently undergoing phase I clinical trials in a variety of hematological malignancies (Table 3). Here, MCL1 is linked to hematologic disorder.